利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.013 秒)

    Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
    5.
    发明公开
    Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates 失效
    程序长期减少体脂肪贮存，胰岛素抵抗，高胰岛素血症和高血糖症在脊椎动物

    公开(公告)号：EP0917874A1

    公开(公告)日：1999-05-26

    申请号：EP98110831.9

    申请日：1991-01-07

    申请人： LOUISIANA STATE UNIVERSITY AGRICULTURAL AND MECHANICAL COLLEGE

    发明人： Cincotta, Anthony ,  Meier, Albert

    IPC分类号： A61K31/48

    CPC分类号： A61K31/496 ,  A61K31/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  G01N33/74 ,  Y10S514/866 ,  A61K2300/00

    摘要： A process for the long term modification and regulation of lipid metabolism -- generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes) -- by administration (i.e., by feed or injection into the bloodstream) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.

    摘要翻译： 一种用于脂质代谢的长期修饰和调节过程 - 基因的反弹，以减少肥胖，胰岛素抵抗和高胰岛素血症或高血糖症，或两者（论文都是非胰岛素的标志相关的，或II型糖尿病） - 通过施用（即 通过进料或注射至血流中）给脊椎动物，动物或人类，多巴胺激动剂，例如，溴隐亭。 溴隐亭的管理是在过度依赖于脂肪和类似物种的精益成员正常的昼夜节律天的有限时间内做出。 在减少身体脂肪堆积的治疗依据波峰催乳，和催乳素峰值和峰值糖皮质激素，血中浓度的同类品种的精益成员建立的昼夜节律是每天定时序列肥胖的物种产生。 胰岛素抵抗和高胰岛素血症和高血糖症，或两者兼而有之，因此可以在人类中治疗对应的治疗控制在一个长期的基础上做的肥胖。 短期内每天注射激素复位时间在大脑的神经中心产生长期影响。

    Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type I (HIV-1) GP120 and methods of use
    6.
    发明公开
    Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type I (HIV-1) GP120 and methods of use 失效
    免疫试剂与人类免疫缺陷病毒I（HIV-I）GP120和它们的使用方法的一个保守的表位反应性的。

    公开(公告)号：EP0459779A1

    公开(公告)日：1991-12-04

    申请号：EP91304840.1

    申请日：1991-05-29

    申请人： Cedars-Sinai Medical Center ,  LOUISIANA STATE UNIVERSITY AGRICULTURAL AND MECHANICAL COLLEGE

    发明人： Ho, David Da-i ,  Robinson, James Edmun

    IPC分类号： C12P21/08 ,  C12N5/10 ,  A61K39/42 ,  G01N33/569 ,  G01N33/577

    CPC分类号： C07K14/70514 ,  A61K38/00 ,  C07K16/1063 ,  C07K16/462 ,  C07K2317/24 ,  C07K2317/732

    摘要： The invention features immunoreagents which neutralize the Human Immunodeficiency Virus Type 1 (HIV-1) by binding to a novel conserved epitope of the HIV-1 gp120. These immunoreagents exhibit a broad neutralizing effect upon HIV attachment to host cells, and are therefore useful in the detection, prevention, amelioration and treatment of HIV disease, primarily AIDS (Acquired Immunodeficiency Syndrome) and ARC (AIDS Related Complex). More particularly, the invention relates to novel human monoclonal antibodies selectively reactive to a conserved conformation dependent determinant of the HIV-1 gp120, derivatives thereof, cell lines that produce these antibodies, and the use of the monoclonal antibodies and their derivatives for the detection, prevention, amelioration and treatment of HIV related disease.

    摘要翻译： 本发明的特征哪通过结合至HIV-1的gp120的新的保守表位的中和人免疫缺陷病毒1型（HIV-1）免疫试剂。 这些免疫试剂表现出在HIV附着的广泛中和作用对宿主细胞，并且在检测因此，预防，改善和治疗HIV疾病，主要是AIDS（获得性免疫缺陷综合征）和ARC（AIDS相关复合体）是有用的。 更具体地，本发明涉及新的人单克隆抗体与HIV-1的gp120的保守构象依赖性决定簇选择性反应，其衍生物，细胞系确实产生合成抗体，和使用用于检测的单克隆抗体和它们的衍生物， 预防，改善和治疗艾滋病相关的疾病。

    Dopamine agonists for treating type II diabetes
    9.
    发明公开
    Dopamine agonists for treating type II diabetes 失效
    Dopaminagonisten zur Behandlung des Typs II-Diabetes。

    公开(公告)号：EP0440333A2

    公开(公告)日：1991-08-07

    申请号：EP91300083.2

    申请日：1991-01-07

    申请人： LOUISIANA STATE UNIVERSITY AGRICULTURAL AND MECHANICAL COLLEGE

    发明人： Cincotta, Anthony ,  Meier, Albert

    IPC分类号： A61K31/00 ,  A61K31/48

    CPC分类号： A61K31/496 ,  A61K31/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/166 ,  A61K31/195 ,  A61K31/221 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/435 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/46 ,  A61K31/475 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/54 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/695 ,  A61K38/2257 ,  A61K45/06 ,  G01N33/74 ,  Y10S514/866 ,  A61K2300/00

    摘要： A process for the long term modification and regulation of lipid metabolism -- generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes) -- by administratlon (i.e., by feed or injection into the bloodstream) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.

    摘要翻译： 长期改变和调节脂质代谢的过程 - 通常是通过给药方式（即，通过降低肥胖，胰岛素抵抗和高胰岛素血症或高血糖症）或两者（这些是非胰岛素依赖型或II型糖尿病的特征） 通过饲养或注射到血液中）到脊髓动物或动物或人类的多巴胺激动剂，例如溴隐亭。 溴隐亭的施用在一段时间内在有限的时间内进行，取决于类似物种的脂肪和瘦成员的正常昼夜节律。 基于妊娠峰值催乳素的昼夜节律，峰值催乳素和高糖类糖皮质激素，为类似物种的精液成员建立的血液水平，以每日定时序列处理肥胖物种，导致身体脂肪沉积减少。 胰岛素抵抗和高胰岛素血症和高血糖症或两者都可以通过与肥胖症治疗相对应的治疗长期控制。 短期每日注射在脑神经中枢复位荷尔蒙时机产生长期效应。